Xiaoyu Nie

Education

Ph.D., policy analysis, Pardee RAND Graduate School; M.S.P.H., Johns Hopkins Bloomberg School of Public Health; B.A., health policy and management, Fudan University

Summary of Experience

Dr. Nie specializes in the application of economic theories and statistical methods in health economics and outcomes research (HEOR). Her areas of expertise include measuring the burden of illness, assessing treatment patterns, evaluating the impacts of health care innovations on utilization and health outcomes, and comparing clinical and cost effectiveness among treatments. She has experience conducting analyses using real-world data (RWD) sources such as insurance claims and electronic health records, developing cost-effectiveness models, and supporting product launches. She has worked across a variety of therapeutic areas, including oncology, autoimmune diseases, hematology, cardiovascular diseases, kidney diseases, and COVID-19. She has published her work in a number of peer-reviewed journals and presented at various clinical and economic research conferences.

Selected Publishing

• Tolvaptan and Number Needed to Harm in Autosomal Dominant Polycystic Kidney Disease

  Kidney Medicine, 2024
  2024

  Betts KA, Nunna S, Kumar R, Nie X, Fernandes AW

  HEOR, Epidemiology & Market Access
• Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: Analysis of Number Needed To Treat and Number Needed To Harm

  Clinical Therapeutics, 2023
  2023

  Sugarman R, Betts KA, Nie X, Hartman J, Nguyen H

  HEOR, Epidemiology & Market Access
• Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective

  PharmacoEconomics, 2022
  2022

  Pratz KW, Chai X, Xie J, Yin L, Nie X, Montez M, Iantuono E, Downs L, Ma E

  HEOR, Epidemiology & Market Access